Loading...
01/11 16:16
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects mixed sentiments. While there is optimism around EMROSI's launch and market access, concerns exist regarding generic competition affecting revenue, increased SG&A expenses, and net losses. The Q&A section highlighted management's reluctance to provide detailed guidance, which could unsettle investors. However, improved gross margins and strong initial revenue from EMROSI provide some optimism. The overall sentiment is neutral, with potential for both positive and negative outcomes depending on EMROSI's future performance.
Net Product Revenue $15 million in Q2 2025, compared to $14.9 million in Q2 2024, a slight increase. This includes $2.8 million from the launch of EMROSI, offset by a $2.3 million decline in Accutane revenue due to generic competition.
Gross Margin 67% in Q2 2025, up from 61% in Q2 2024, driven by a favorable product sales mix, notably EMROSI and Accutane.
R&D Costs $0 in Q2 2025, compared to $900,000 in Q2 2024. The prior year's costs were related to EMROSI pre-approval project expenses.
SG&A Expenses $11.9 million in Q2 2025, up from $10.3 million in Q2 2024, an increase of $1.6 million due to operational activities related to the launch and commercialization of EMROSI.
Net Loss $3.8 million in Q2 2025, compared to $3.4 million in Q2 2024. The increase is attributed to higher SG&A expenses.
Cash Position $20.3 million as of the end of Q2 2025, unchanged from December 31, 2024, reflecting minimal cash burn year-to-date.
EMROSI launch: EMROSI, a best-in-class oral rosacea treatment, was introduced to the market in Q2 2025. It generated $2.8 million in sales, contributing to a total net product revenue of $15 million for the quarter. Prescription volumes have shown strong uptake, with over 12,800 prescriptions generated by the end of July and a 10% share of new prescription demand among dermatology writers.
Market access for EMROSI: Payer access for EMROSI increased from 30% of commercial lives in May to 65% in July, demonstrating strong early traction in the market.
Operational efficiencies: Gross margin increased to 67% in Q2 2025 from 61% in the prior year period. Operating expenses remained mostly flat year-over-year, and cash management discipline resulted in minimal cash use for the quarter.
Focus on growth brands: The company is prioritizing the growth of EMROSI and QBREXZA to offset declines in Accutane sales due to generic competition. EMROSI is positioned as a potential standard of care for rosacea treatment.
Accutane sales decline: Sales of Accutane have been pressured due to aggressive pricing from generic competition, leading to a decline in revenue from this product compared to the prior year period. This poses a risk to the company's revenue stability.
Generic competition: The presence of aggressive pricing from generic competitors is impacting the sales of Accutane, which could continue to affect the company's financial performance.
Increased SG&A expenses: Selling, General, and Administrative (SG&A) expenses increased by $1.6 million compared to the prior year, primarily due to operational activities related to the launch and commercialization of EMROSI. This increase in expenses could pressure profitability.
Net loss: The company reported a net loss of $3.8 million for the second quarter of 2025, slightly higher than the $3.4 million loss in the same period of 2024. This ongoing loss could impact financial sustainability.
Dependence on EMROSI's success: The company's future growth and profitability heavily rely on the success of EMROSI. Any challenges in maintaining prescription growth, payer access, or prescriber adoption could adversely impact the company's strategic objectives.
Revenue Growth: The company expects strong revenue growth driven by the continued prescription ramp of EMROSI, its best-in-class oral rosacea treatment. EMROSI is anticipated to generate high contribution margins and provide significant leverage toward overall profitability and growth.
Market Penetration: EMROSI has achieved over 10% share of new prescription demand among dermatology writers within its third month of promotion. The company aims to expand the base of EMROSI prescribers and grow prescription volume further in the second half of the year.
Payer Access: Payer access for EMROSI has increased significantly from 30% of commercial lives in May to approximately 65% in July. The company plans to continue expanding payer access to facilitate prescription fulfillment.
Profitability: Journey Medical Corporation is focused on becoming sustainably EBITDA positive later in 2025, leveraging its dermatology-focused commercial organization and fixed costs.
Operational Focus: The company will prioritize expanding EMROSI's prescriber base, growing prescription volume, and converting prescription volume into revenue in the second half of the year.
The selected topic was not discussed during the call.
The earnings call reveals strong revenue growth driven by EMROSI, improved EBITDA, and positive cash flow. The Q&A section highlights successful prescriber expansion and revenue per script improvements, although there are concerns about gross-to-net revenue guidance and prescriber retention data. Despite these uncertainties, the overall sentiment is positive due to the strong financial metrics, optimistic guidance, and strategic focus on expanding EMROSI's market presence.
The earnings call reflects mixed sentiments. While there is optimism around EMROSI's launch and market access, concerns exist regarding generic competition affecting revenue, increased SG&A expenses, and net losses. The Q&A section highlighted management's reluctance to provide detailed guidance, which could unsettle investors. However, improved gross margins and strong initial revenue from EMROSI provide some optimism. The overall sentiment is neutral, with potential for both positive and negative outcomes depending on EMROSI's future performance.
The earnings call highlights strong financial performance, with improved gross margins and reduced net loss. The launch of Ambrosi has shown promising initial sales and market acceptance, supported by positive clinical validation and increased market access. Despite competitive pressures and challenges in legacy business, management's strategic focus on expanding access and prescription volume is evident. The Q&A session reveals analyst concerns about legacy business trends, but positive feedback on Ambrosi's efficacy. Overall, the company's solid cash position and growth potential for Ambrosi suggest a positive outlook, likely leading to a stock price increase of 2% to 8%.
The earnings call reflects a positive sentiment overall. Emrosi's launch into a $1 billion market, strong clinical results, and increasing market access are promising. Financials show improved revenue and margins, despite a net loss. The Q&A reveals confidence in continued revenue growth and positive prescriber feedback. While there are risks like regulatory and competitive pressures, the company's strategic focus on expanding market access and improving financial health supports a positive outlook. The lack of specific guidance is a concern, but not enough to outweigh the positive factors.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
